Rubicon Research’s subsidiary -- Advagen Holdings Inc. (Advagen) has entered into a definitive agreement with GEn1E Lifesciences Inc. (Gen1E), to acquire Series Prime Preferred Stock in tranches, for a total consideration of up to $3 million. Series Prime Preferred Stock, convertible into around 2.2% of Gen1E’s common stock ownership subject to achievement of all milestones.
Gen1E is a pharmaceutical company with a pipeline of product candidates under development. GEn1E is based in Palo Alto, California, with a laboratory in Mountain View, California, USA.
Rubicon Research is a pharmaceutical formulations company, driven by innovation through focused research and development, with an increasing portfolio of speciality products and drug-device combination products targeting regulated markets and in particular the United States.
| Company Name | CMP |
|---|---|
| Wework India Managem | 546.40 |
| Rubicon Research | 919.55 |
| Aegis Vopak Terminal | 197.10 |
| Mallcom | 1100.00 |
| Inducto Steel | 52.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: